Related Experiment Video
Updated: Sep 7, 2025
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
Published on: May 14, 2019
Game changer in cancer treatment in Switzerland
Background:
It is time for a game-changer in the cancer pathway in Switzerland and around the world. COVID-19 has made this more evident than ever. The prevalence, complexity, and cost of cancer care are increasing in Switzerland. Losses in efficiency, resources, and inappropriate attribution hinder health outcomes. This study examined opportunities for improvement across the cancer path, with a focus on patient-provider communication, effective policies and approaches to strengthen interprofessional collaboration.
Methods:
A qualitative study was undertaken. Key stakeholders, selected on the basis of their expertise in different areas of the cancer pathway, were assessed through interviews. The need to develop and implement innovative strategies to prevent and treat cancer was investigated, and key recommendations were identified for discussion with politicians and policy makers. Inductive content analysis was conducted.
Results:
There is a prominent need for collaboration and cross-sectoral action in cancer, encompassing clinical disciplines, communication strategies, and professional attitudes. The need and demand for collaboration responds to a highly fragmented cancer landscape in Switzerland, with a hierarchical organization of medical care entities and much competition. COVID-19 made these gaps more visible and highlighted the need to develop a new systematic approach and contingency plan to protect the most vulnerable.
Conclusion:
Pressing developments are occurring in the health care system given the increasing prevalence of some cancers, the demographics of the Swiss population, the growing number of cancer survivors, and the consequences of the COVID-19 pandemic.
Policy Summary:
More fundamental solutions and policies should be developed and implemented to meet patient needs and increase health outcomes: are providers and patients taking responsibility for change? Will business interests and the power play boycott policy development? Change must start now, with policymakers, patients, providers and insurers joining forces.
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...